Toggle light / dark theme

ClickFix Lures Deploy ChainScript RAT Using Polygon to Rotate C2 Infrastructure

The cybersecurity company described the activity as part of a broader pattern of attacks that employ trusted services and large language model (LLM) shared chats to serve fake installation instructions, while bypassing browser warnings, URL inspection, and Safe Browsing heuristics.

In a report published last month, Microsoft said it observed a macOS ClickFix campaign propagating MacSync and Atomic Stealer using a cluster of no less than 250 look-alike domains.

“The campaign evolved from broadly serving ClickFix lures to using a server-side browser-fingerprinting gate that shows the lure primarily to visitors whose environment appears consistent with a genuine macOS browser,” it said. “This cloaking limits visibility for crawlers, sandboxes, and some automated analysis workflows.”

Microsoft to retire Microsoft 365 Companion apps in December

Microsoft announced that it will retire the Calendar, People, and Files Microsoft 365 companion apps on December 16 and urged admins to remove them from managed devices in their organization.

This follows Microsoft’s October 2025 announcement that it will begin automatically installing them on all Windows 11 enterprise devices with the Microsoft 365 desktop client apps by the end of December 2025.

The Microsoft 365 companion apps integrate Copilot for contextual AI assistance and can help locate people within the organization, access Microsoft 365 and locally stored files, and manage one’s schedule using the Microsoft 365 calendar from the Windows 11 taskbar.

4D AI Model Decodes Mitochondrial Drug Effects

A 4D AI model uses mitochondrial shape and movement to predict how drugs affect cells, potentially speeding up drug discovery. [ https://www.labroots.com/trending/biotech-and-pharma/31081/4…-effects-2](https://www.labroots.com/trending/biotech-and-pharma/31081/4…-effects-2)


How can AI be used to improve drug discovery and delivery? This is what two recent studies published in Cell hopes to address as a team of researchers investigated a new method for delivering drugs to mitochondria, with mitochondria often being dubbed as the “powerhouse” of the cell. This study has the potential to help scientists, medical professionals, and the public better understand new methods for drug discovery and delivery and how it can improve patient lives.

For the studies, which were published in July 2026 and September 2026, respectively, the researchers used a combination of deep-learning AI models and 4D movies created from a novel method called 4D lattice light-sheet microscopy to ascertain how mitochondria behave when it’s healthy and not. The method of 4D lattice light-sheet microscopy involves imaging 3D movement and behavior of mitochondria over time. The primary motivation behind the study was to create new methods for studying mitochondria, which traditionally were studied using 2D snapshots.

In the end, and in one study, the researchers successfully created digital models of mitochondria, which they dubbed “digital twins”, to analyze how the mitochondria behaved compared to real cells. For the other study, the researchers and used the AI model to observe about 40,000 4D movies showing drug-treated cells to analyze how the mitochondria reacted.

How Much Does A Humanoid Robot Cost In 2026

Humanoid robot price alone excludes integration labor, maintenance, downtime, and software licensing — all of which can add 30–50% to the first-year total cost of ownership on top of the purchase or subscription figure quoted by the manufacturer.

Strategic Impact: Humanoid robot cost is bifurcating into two completely different markets — cheap, real, shippable Chinese hardware and expensive, largely theoretical Western platforms — and buyers who don’t separate the two end up comparing numbers that were never meant to be compared.

Adam Riess on Dark Energy and the Unruly Universe

It would be easy to assume a cosmologist suits only science conferences. In practice, Riess resonates just as strongly with business, finance, and leadership audiences, because the deeper subject of his work is how to think.

His talks are, at their core, about following evidence that contradicts consensus, telling a real signal from noise, and holding your nerve when the data points somewhere uncomfortable. Those are precisely the disciplines that separate good decisions from bad ones in any high-stakes field.

It is a sensibility he shares with fellow Nobel laureate Michael Spence, whose work on the economics of AI rests on the same evidence-first rigor. For any organization navigating genuine uncertainty, Riess offers not just wonder but a model of how to reason under it.